ReviewCurrent opinion in organ transplantation2012
Cardiac xenotransplantation: progress and challenges.
Review in Current opinion in organ transplantation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 82 citations in OpenAlex.
- Genetically engineered porcine liver: a new era in transplantation.International journal of surgery (London, England) · 2026Article
- Gene-edited pig cardiac xenotransplantation as a bridge to allotransplantation in infants: Progress in a pig-to-baboon model.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2026Article
- Current status of xenotransplantation from an immunobiological standpoint.Clinical transplantation and research · 2025Review
- Early Results of an Infant Model of Orthotopic Cardiac Xenotransplantation.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2025Article
- Natural biomaterials in the management of the aortic valve pathology. Biomedical and clinical aspects: A review.Biomolecules & biomedicine · 2025Review
- Commentary: Molecular responses in pig heart to human xenotransplantation unveiled by longitudinal multi-omic profiling.Clinical and translational medicine · 2025Article
- [Xenotransplantation of solid organs].Chirurgie (Heidelberg, Germany) · 2024Review
- Physiological basis for xenotransplantation from genetically modified pigs to humans.Physiological reviews · 2024Review
- Current Status of Cardiac Xenotransplantation: Report of a Workshop of the German Heart Transplant Centers, Martinsried, March 3, 2023.The Thoracic and cardiovascular surgeon · 2024Article
- Progress in Orthotopic Pig Heart Transplantation in Nonhuman Primates.Transplant international : official journal of the European Society for Organ Transplantation · 2024Review
- Pig-to-human heart xenotransplantation in two recently deceased human recipients.Nature medicine · 2023Article
- Review
- Cardiac xenotransplantation: from concept to clinic.Cardiovascular research · 2023Review
- Preclinical rationale and current pathways to support the first human clinical trials in cardiac xenotransplantation.Human immunology · 2023Article
- Pig heart and lung xenotransplantation: Present status.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation · 2022Article
- The potential of genetically engineered pig heart transplantation in infants with complex congenital heart disease.Pediatric transplantation · 2022Review
- Cardiac and Pulmonary Histopathology in Baboons Following Genetically-Engineered Pig Orthotopic Heart Transplantation.Annals of transplantation · 2022Article
- Cardiac Xenotransplantation: Challenges, Evolution, and Advances.JACC. Basic to translational science · 2022Review
- Effects of human TFPI and CD47 expression and selectin and integrin inhibition during GalTKO.hCD46 pig lung perfusion with human blood.Xenotransplantation · 2022Article
- Cardiac xenotransplantation: a promising way to treat advanced heart failure.Heart failure reviews · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
Abstract
purpose of reviewCardiac xenotransplantation (CXTx) remains a promising approach to alleviate the chronic shortage of donor hearts. This review summarizes recent results of heterotopic and orthotopic CXTx, highlights the role of non-Gal antibody in xenograft rejection, and discusses challenges to clinical orthotopic CXTx. RECENT
findingsPigs mutated in the α 1,3 galactosyltransferase gene (GTKO pigs) are devoid of the galactose α1,3 galactose (αGal) carbohydrate antigen. This situation effectively eliminates any role for anti-Gal antibody in GTKO cardiac xenograft rejection. Survival of heterotopic GTKO cardiac xenografts in nonhuman primates continues to increase. GTKO graft rejection commonly involves vascular antibody deposition and variable complement deposition. Non-Gal antibody responses to porcine antigens associated with inflammation, complement, and hemostatic regulation and to new carbohydrate antigens have been identified. Their contribution to rejection remains under investigation. Orthotopic CXTx is limited by early perioperative cardiac xenograft dysfunction (PCXD). However, hearts affected by PCXD recover full cardiac function and orthotopic survival up to 2 months without rejection has been reported. SUMMARY: CXTx remains a promising technology for treating end-stage cardiac failure. Genetic modification of the donor and refinement of immunosuppressive regimens have extended heterotopic cardiac xenograft survival from minutes to in excess of 8 months.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.